Vistagen Therapeutics (VTGN) Competitors $2.32 -0.04 (-1.69%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTGN vs. AQST, TNXP, TVRD, PVLA, ALLO, GLUE, TNGX, CRVS, SLDB, and IMMPShould you be buying Vistagen Therapeutics stock or one of its competitors? The main competitors of Vistagen Therapeutics include Aquestive Therapeutics (AQST), Tonix Pharmaceuticals (TNXP), Cara Therapeutics (TVRD), Palvella Therapeutics (PVLA), Allogene Therapeutics (ALLO), Monte Rosa Therapeutics (GLUE), Tango Therapeutics (TNGX), Corvus Pharmaceuticals (CRVS), Solid Biosciences (SLDB), and Immutep (IMMP). These companies are all part of the "pharmaceutical products" industry. Vistagen Therapeutics vs. Its Competitors Aquestive Therapeutics Tonix Pharmaceuticals Cara Therapeutics Palvella Therapeutics Allogene Therapeutics Monte Rosa Therapeutics Tango Therapeutics Corvus Pharmaceuticals Solid Biosciences Immutep Aquestive Therapeutics (NASDAQ:AQST) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability. Does the media prefer AQST or VTGN? In the previous week, Aquestive Therapeutics had 3 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 5 mentions for Aquestive Therapeutics and 2 mentions for Vistagen Therapeutics. Vistagen Therapeutics' average media sentiment score of 1.87 beat Aquestive Therapeutics' score of 1.60 indicating that Vistagen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Vistagen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility and risk, AQST or VTGN? Aquestive Therapeutics has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Does the MarketBeat Community favor AQST or VTGN? Vistagen Therapeutics received 64 more outperform votes than Aquestive Therapeutics when rated by MarketBeat users. Likewise, 72.31% of users gave Vistagen Therapeutics an outperform vote while only 68.55% of users gave Aquestive Therapeutics an outperform vote. CompanyUnderperformOutperformAquestive TherapeuticsOutperform Votes21868.55% Underperform Votes10031.45% Vistagen TherapeuticsOutperform Votes28272.31% Underperform Votes10827.69% Is AQST or VTGN more profitable? Aquestive Therapeutics has a net margin of -59.75% compared to Vistagen Therapeutics' net margin of -6,777.08%. Aquestive Therapeutics' return on equity of 0.00% beat Vistagen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics-59.75% N/A -33.96% Vistagen Therapeutics -6,777.08%-48.12%-43.80% Which has better earnings and valuation, AQST or VTGN? Aquestive Therapeutics has higher revenue and earnings than Vistagen Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Vistagen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquestive Therapeutics$54.23M6.06-$7.87M-$0.59-5.61Vistagen Therapeutics$698K95.93-$29.36M-$1.48-1.57 Do insiders & institutionals have more ownership in AQST or VTGN? 32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are owned by institutional investors. 8.4% of Aquestive Therapeutics shares are owned by insiders. Comparatively, 1.3% of Vistagen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate AQST or VTGN? Aquestive Therapeutics presently has a consensus target price of $10.14, suggesting a potential upside of 206.43%. Given Aquestive Therapeutics' higher probable upside, research analysts clearly believe Aquestive Therapeutics is more favorable than Vistagen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquestive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Vistagen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 SummaryAquestive Therapeutics beats Vistagen Therapeutics on 11 of the 19 factors compared between the two stocks. Get Vistagen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTGN vs. The Competition Export to ExcelMetricVistagen TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.96M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-1.578.6727.1419.96Price / Sales95.93262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book0.836.597.064.69Net Income-$29.36M$143.75M$3.23B$248.14M7 Day Performance-2.11%3.72%2.67%2.39%1 Month PerformanceN/A11.01%8.82%6.05%1 Year Performance-37.13%3.87%31.44%13.60% Vistagen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTGNVistagen Therapeutics1.4137 of 5 stars$2.32-1.7%N/A-37.4%$66.96M$698K-1.5740News CoveragePositive NewsAQSTAquestive Therapeutics1.7615 of 5 stars$2.81+3.7%$10.14+261.0%+21.4%$279.11M$54.23M-6.24160Positive NewsAnalyst RevisionTNXPTonix Pharmaceuticals3.3562 of 5 stars$38.06-4.3%$585.00+1,437.0%-82.3%$278.79M$10.04M-0.0150News CoverageGap DownTVRDCara TherapeuticsN/A$29.75+5.0%$65.00+118.5%N/A$278.49MN/A0.0080News CoverageAnalyst ForecastGap UpHigh Trading VolumePVLAPalvella Therapeutics4.0465 of 5 stars$25.14+4.2%$46.29+84.1%N/A$277.95M$42.81M-2.08N/APositive NewsAnalyst RevisionHigh Trading VolumeALLOAllogene Therapeutics3.9877 of 5 stars$1.27+8.5%$8.44+564.9%-43.1%$277.79M$22K-0.81310GLUEMonte Rosa Therapeutics2.3993 of 5 stars$4.50+7.7%$15.50+244.4%+18.0%$276.80M$159.49M-2.4690TNGXTango Therapeutics2.164 of 5 stars$2.54+14.4%$12.20+380.3%-31.5%$275.32M$40.99M-2.1590News CoveragePositive NewsAnalyst RevisionGap DownHigh Trading VolumeCRVSCorvus Pharmaceuticals2.6686 of 5 stars$4.03+6.6%$15.00+272.2%+110.3%$274.72MN/A-4.3330News CoverageAnalyst RevisionSLDBSolid Biosciences3.7693 of 5 stars$3.54+10.3%$14.90+320.9%-38.6%$274.40M$8.09M-1.16100Analyst RevisionGap UpHigh Trading VolumeIMMPImmutep1.4091 of 5 stars$1.86-1.1%$7.00+276.3%-31.7%$271.63M$5.14M0.002,021 Related Companies and Tools Related Companies AQST Alternatives TNXP Alternatives TVRD Alternatives PVLA Alternatives ALLO Alternatives GLUE Alternatives TNGX Alternatives CRVS Alternatives SLDB Alternatives IMMP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTGN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vistagen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vistagen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VTGN Stock Free VTGN Stock Alerts